Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China : Results from two studies
WHO UNIVERSAL TRIAL NUMBERS (UTNS): U1111-1174-4615 and U1111-1174-4698.
CLINICALTRIALS.GOV: NCT04210349 and NCT03430089.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 18(2022), 6 vom: 30. Nov., Seite 2132798 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Xiaoqiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 20.12.2022 Date Revised 21.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT04210349, NCT03430089 Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2022.2132798 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348423659 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348423659 | ||
| 003 | DE-627 | ||
| 005 | 20231226205511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2022.2132798 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348423659 | ||
| 035 | |a (NLM)36328438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Xiaoqiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China |b Results from two studies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04210349, NCT03430089 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a WHO UNIVERSAL TRIAL NUMBERS (UTNS): U1111-1174-4615 and U1111-1174-4698 | ||
| 520 | |a CLINICALTRIALS.GOV: NCT04210349 and NCT03430089 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a China | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a inactivated influenza vaccine | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a quadrivalent | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 700 | 1 | |a Park, Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Shengli |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shuangmin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanxia |e verfasserin |4 aut | |
| 700 | 1 | |a Syrkina, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Lavis, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Chenyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jieqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Samson, Sandrine I |e verfasserin |4 aut | |
| 700 | 1 | |a de Bruijn, Iris A |e verfasserin |4 aut | |
| 700 | 0 | |a FSQ01 and FSQ02 Study Groups |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 18(2022), 6 vom: 30. Nov., Seite 2132798 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:6 |g day:30 |g month:11 |g pages:2132798 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2022.2132798 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 6 |b 30 |c 11 |h 2132798 | ||